{
    "relation": [
        [
            "",
            "Sitagliptin",
            "Placebo"
        ],
        [
            "Description",
            "Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily [t.i.d.])",
            "Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)"
        ]
    ],
    "pageTitle": "Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01177384?sect=X01256&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989891.18/warc/CC-MAIN-20150728002309-00094-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 859810137,
    "recordOffset": 859793743,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups All participants randomized population. The participant flow module includes the second sequential randomization of a participant in the placebo group. Data for the second sequential randomization were excluded from the efficacy and safety analyses and the reason for not completed was a protocol violation. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Sitagliptin phosphate Drug: Comparator: Placebo Drug: Acarbose Drug: Glimepiride Interventions: Type 2 Diabetes Mellitus Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Sitagliptin \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 191 \u00a0 \u00a0 190 [1] COMPLETED \u00a0 \u00a0 177 \u00a0 \u00a0 164 \u00a0 NOT COMPLETED \u00a0 \u00a0 14 \u00a0 \u00a0 26 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 6 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}